Coralis Health has partnered with biotechnology company LinusBio to further streamline autism diagnosis and early intervention. This partnership is a major step forward in trying to help thousands of children and their families, who are currently bogged down in a system of waitlists and lack of experienced providers. This collaboration combines LinusBio’s breakthrough biomarker testing with Coralis Health’s specialized care platform, creating a seamless pathway from early screening to diagnosis and intervention.
This integrated service is designed primarily for families who have concerns about their child’s development, and are seeking both objective screening insights and expert diagnostic evaluation. Healthcare and service providers can also leverage this streamlined pathway to offer their patients a comprehensive diagnostic solution that reduces wait times for specialized autism evaluations.
Streamlining the Path to Diagnosis and Intervention
Evidence shows that early diagnosis and intervention are crucial for improved outcomes, yet many families still encounter lengthy delays in accessing the diagnostic support they need. Currently, families concerned about autism often face years-long waitlists for diagnostic evaluations, delaying access to crucial early interventions. This new partnership creates a direct bridge between biomarker screening and comprehensive virtual diagnostic services, significantly reducing the time between initial concern and professional evaluation.
“Our goal has always been to make sure that children are connected to life-changing therapies in a timely manner, while providing the highest quality care. We also want to reduce the burden on clinicians, by finding ways to standardize care in a space that’s currently too dependent on individual clinical expertise and training,” explained Dr. Ayesha Cheema-Hasan, founder and CEO of Coralis Health. “By leveraging technology thoughtfully, we aim to bridge the gap in access, and ensure that every child has the opportunity to thrive regardless of where they start.”
Comprehensive End-to-End Support Means Less Waiting and Better Care
By accessing this new integrated service, families have a complete diagnostic solution, from initial biomarker screening through comprehensive autism evaluation. Coralis Health’s diagnostic team conducts thorough assessments using clinically validated tools, delivering detailed diagnostic reports that families can use to access essential services and interventions. Testing is available for children 16 months and older.
“This partnership represents exactly the kind of innovation needed to transform autism care,” said Dr. Manish Arora, founder and CEO of LinusBio. “By partnering with Coralis Health, we’re creating a comprehensive solution that takes families from screening through diagnosis and into intervention – all through a single, coordinated pathway.”
Dr. Angelica Robles, co-founder and chief medical officer of Coralis Health adds, “The reason we founded Coralis Health is to help families connect to therapists early, access trusted resources, and make informed decisions, through a single reliable platform that brings together information, quality care, and essential services. Partnering with LinusBio is just one of the many ways we’re using smart solutions/technology to make this vision a reality.”
This unique service is now available in 10 states – Alaska, Colorado, Connecticut, Illinois, Maryland, North Carolina, Rhode Island, Tennessee, Virginia, Washington – and Washington, D.C.
